Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our high-tech, dedicated method is applied to construct targeted libraries for receptors.


 

Fig. 1. The screening workflow of Receptor.AI

It features thorough molecular simulations of the receptor within its native membrane environment, complemented by ensemble virtual screening that considers its conformational mobility. For dimeric or oligomeric receptors, the full functional complex is constructed, and tentative binding sites are determined on and between the subunits to cover the entire spectrum of potential mechanisms of action.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P32241

UPID:
VIPR1_HUMAN

ALTERNATIVE NAMES:
Pituitary adenylate cyclase-activating polypeptide type II receptor; VPAC1

ALTERNATIVE UPACC:
P32241; A5JUT9; B3KPV1; B4DEB5; B4DGI4; F5H1F5; G3V0I1; Q15871; Q6P2M6

BACKGROUND:
The Vasoactive intestinal polypeptide receptor 1, known as VPAC1, serves as a receptor for VIP, playing a pivotal role in mediating cellular responses to this peptide. Through the activation of G proteins and subsequent adenylyl cyclase activation, VPAC1 is integral in the regulation of cyclic AMP levels in cells. Its binding affinity is characterized by a preference for VIP, followed by PACAP-27 and PACAP-38.

THERAPEUTIC SIGNIFICANCE:
The exploration of Vasoactive intestinal polypeptide receptor 1's function offers a promising avenue for the development of therapeutic interventions. Given its key role in modulating cyclic AMP pathways, targeting VPAC1 could provide innovative solutions for treating diseases associated with these signaling mechanisms.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.